News

Erythromycin in babies and infants has been associated with an increased risk of infantile hypertrophic pyloric stenosis.

Experts from 13 national bodies, including seven Royal Colleges, have joined forces to launch new practical guidance to support doctors and other health professionals around valproate use in women and girls in their reproductive years.

This guidance, updated in December 2020 and endorsed by RCPCH, has been produced to inform all healthcare professionals of best practice around the use and prescribing of valproate. It supports them to navigate situations that could arise as a result of prescribing valproate to women during childbea...

Following recent publication of the REMAP-CAP trial for hydrocortisone and a meta-analysis of corticosteroids, the World Health Organization (WHO) has recently issued new interim guidance recommending the use of systemic corticosteroids in severe and critical COVID-19 disease.

Ranitidine products (Brand names including Zantac®) were voluntarily withdrawn by manufacturers in October 2019, because of fears that they may contain low levels of an impurity called NMDA.

The RCPCH/NPPG Medicines Committee has recently been informed of a severe adverse reaction in a six-month old child with anisocoria who had been administered apraclonidine 1% to help exclude Horner syndrome.

The Medicines and Healthcare products Regulatory Agency (MHRA) is requesting that healthcare professionals report any suspected side effects or safety concerns with e-cigarettes and the e-liquids used for vaping to the Yellow Card Scheme.

Dr Mike Linney, Registrar and Chair of the Ethics Committee for RCPCH, welcomes recent guidance from NICE, but notes the urgent need for high quality, independent research on this medicine to provide the best possible care for children with complex epilepsy.

Domperidone is no longer licensed for use in children younger than 12 years or those weighing less than 35 kg because of a lack of evidence for benefit.

Last week, NICE published draft recommendations on the use of cannabis-based medicinal products (CBMPs) following evaluation of their clinical and cost-effectiveness, and NHS England published a review aimed at assessing the barriers to prescribing cannabis-based medicinal products where it is safe ...